KPRX
Kiora Pharmaceuticals Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Kiora Pharmaceuticals Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · Mar 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
—
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Kiora Pharmaceuticals Inc.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; no measured co-movers for Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc
1.72
Tall tick = annual report · Source: EDGAR
Largest filed tie
—
Expected move
No implied move.
—
—
| Manager | Value | % base | |
|---|---|---|---|
| Perceptive | $1.2M | 39.66% | new |
| ADAR1 | $441,685 | 15.19% | 0.00% |
| Citadel | $305,109 | 10.49% | +134.21% |
| Two Sigma | $233,523 | 8.03% | new |
| Millennium | $195,151 | 6.71% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Perceptive | $1.2M | 39.66% | new |
| ADAR1 | $441,685 | 15.19% | 0.00% |
| Citadel | $305,109 | 10.49% | +134.21% |
| Two Sigma | $233,523 | 8.03% | new |
| Millennium | $195,151 | 6.71% | new |
+15.77%
shares held · 10 largest managers